Merck
  • Home
  • Search Results
  • Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.

Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.

Brain : a journal of neurology (2014-07-27)
Hélène Hall, Stefanie Reyes, Natalie Landeck, Chris Bye, Giampiero Leanza, Kay Double, Lachlan Thompson, Glenda Halliday, Deniz Kirik
ABSTRACT

The neuropathological substrate of dementia in patients with Parkinson's disease is still under debate, particularly in patients with insufficient alternate neuropathology for other degenerative dementias. In patients with pure Lewy body Parkinson's disease, previous post-mortem studies have shown that dopaminergic and cholinergic regulatory projection systems degenerate, but the exact pathways that may explain the development of dementia in patients with Parkinson's disease remain unclear. Studies in rodents suggest that both the mesocorticolimbic dopaminergic and septohippocampal cholinergic pathways may functionally interact to regulate certain aspects of cognition, however, whether such an interaction occurs in humans is still poorly understood. In this study, we performed stereological analyses of the A9 and A10 dopaminergic neurons and Ch1, Ch2 and Ch4 cholinergic neurons located in the basal forebrain, along with an assessment of α-synuclein pathology in these regions and in the hippocampus of six demented and five non-demented patients with Parkinson's disease and five age-matched control individuals with no signs of neurological disease. Moreover, we measured choline acetyltransferase activity in the hippocampus and frontal cortex of eight demented and eight non-demented patients with Parkinson's disease, as well as in the same areas of eight age-matched controls. All patients with Parkinson's disease exhibited a similar 80-85% loss of pigmented A9 dopaminergic neurons, whereas patients with Parkinson's disease dementia presented an additional loss in the lateral part of A10 dopaminergic neurons as well as Ch4 nucleus basalis neurons. In contrast, medial A10 dopaminergic neurons and Ch1 and Ch2 cholinergic septal neurons were largely spared. Despite variable Ch4 cell loss, cortical but not hippocampal cholinergic activity was consistently reduced in all patients with Parkinson's disease, suggesting significant dysfunction in cortical cholinergic pathways before frank neuronal degeneration. Patients with Parkinson's disease dementia were differentiated by a significant reduction in hippocampal cholinergic activity, by a significant loss of non-pigmented lateral A10 dopaminergic neurons and Ch4 cholinergic neurons (30 and 55% cell loss, respectively, compared with neuronal preservation in control subjects), and by an increase in the severity of α-synuclein pathology in the basal forebrain and hippocampus. Overall, these results point to increasing α-synuclein deposition and hippocampal dysfunction in a setting of more widespread degeneration of cortical dopaminergic and cholinergic pathways as contributing to the dementia occurring in patients with pure Parkinson's disease. Furthermore, our findings support the concept that α-synuclein deposition is associated with significant neuronal dysfunction in the absence of frank neuronal loss in Parkinson's disease.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
乙腈, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
乙腈, anhydrous, 99.8%
Sigma-Aldrich
乙腈, HPLC Plus, ≥99.9%
Sigma-Aldrich
乙腈, for HPLC, for UV, ≥99.9% (GC)
Sigma-Aldrich
乙腈, ACS reagent, ≥99.5%
Sigma-Aldrich
乙腈, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
乙腈 溶液, contains 0.1 % (v/v) trifluoroacetic acid, suitable for HPLC
Sigma-Aldrich
四苯基硼酸钠, ACS reagent, ≥99.5%
Sigma-Aldrich
乙腈, suitable for HPLC-GC, ≥99.8% (GC)
Sigma-Aldrich
乙腈, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99.5% (GC)
Supelco
乙腈, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
乙腈, analytical standard
Sigma-Aldrich
乙腈, biotech. grade, ≥99.93%
Sigma-Aldrich
四苯基硼酸钠, puriss. p.a., ACS reagent, ≥99.5% (NT)
Sigma-Aldrich
乙腈, electronic grade, 99.999% trace metals basis
Sigma-Aldrich
乙腈, ReagentPlus®, 99%
Supelco
残留溶剂-乙腈, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
乙腈, suitable for DNA synthesis, ≥99.9% (GC)
Supelco
四苯基硼酸钠, Selectophore, ≥99.5%
USP
乙腈 溶液, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
乙腈, ≥99.5% (GC)
Sigma-Aldrich
Anti-BTK antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-TMPRSS11D antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Monoclonal Anti-GATM, (N-terminal) antibody produced in mouse, clone 2H7, ascites fluid
Sigma-Aldrich
Anti-TMPRSS11D antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-BTK antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-BTK antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Anti-TMPRSS11D antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-GATM antibody produced in mouse, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
Anti-GATM antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution